Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04071626 · ClinicalTrials.gov registry record · Phase 4
Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure
A Phase 4 study, sponsored by University Hospitals Cleveland Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT04071626 is a Phase 4 study that was terminated before completion, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 9 participants.
The verdict
NCT04071626, a Phase 4 study, was terminated before completion, sponsored by University Hospitals Cleveland Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
This clinical trial will determine if subjects with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM2) receiving sodium-glucose cotransporter 2 (SGLTi2) inhibitor therapy (ertugliflozin) alters cardiac metabolism compared to placebo in a single blinded (to subject), randomized, parallel group, active controlled, single center experimental design.
Interventions
- DRUG Placebo oral tablet
- DRUG Ertugliflozin 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2023-01-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04071626
The ClinicalTrials.gov registry entry for NCT04071626 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04071626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04071626 about?
NCT04071626 is a clinical study titled "Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure". This clinical trial will determine if subjects with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM2) receiving sodium-glucose cotransporter 2 (SGLTi2) inhibitor therapy (ertugliflozin) alters cardiac metabolism compared to placebo in a single blinded (to subj...
What is the current status of trial NCT04071626?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2020-03-01. Estimated completion is 2023-01-11.
What interventions are being tested in trial NCT04071626?
The interventions under investigation include: Placebo oral tablet (DRUG), Ertugliflozin 5 mg (DRUG).
Who is sponsoring clinical trial NCT04071626?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.